BUZZ-Australia's Prescient Therapeutics soars on EU orphan drug tag for cancer therapy

Reuters

Nov 19, 2025

BUZZ-Australia's <a href="https://laohu8.com/S/PTX.AU">Prescient Therapeutics</a> soars on EU orphan drug tag for cancer therapy

** Shares of Prescient Therapeutics PTX.AX rise as much as 29.2% to A$0.062, their highest level since December 23, 2024

** Clinical-stage oncology company heading for best day since December 2024, if gains hold

** Co says European Medicines Agency grants orphan drug designation to PTX-100 for treating cutaneous T-cell lymphoma

** About 4.4 million shares change hand, 3.9x 30-day average

** Stock up 10% this year, including the day's move

(Reporting by John Biju in Bengaluru)

((John.Biju@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2584960552"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2584960552\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2584960552?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-19 08:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584960552","market":"nz","top_or_hot":-1,"title":"BUZZ-Australia's Prescient Therapeutics soars on EU orphan drug tag for cancer therapy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Australia's <a href=\"https://laohu8.com/S/PTX.AU\">Prescient Therapeutics</a> soars on EU orphan drug tag for cancer therapy </title></head><body><p>** Shares of Prescient <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>PTX.AX</span> rise as much as 29.2% to A$0.062, their highest level since December 23, 2024</p><p>** Clinical-stage oncology company heading for best day since December 2024, if gains hold</p><p>** Co says European Medicines Agency <span>grants</span> orphan drug designation to PTX-100 for treating cutaneous T-cell lymphoma</p><p>** About 4.4 million shares change hand, 3.9x 30-day average</p><p>** Stock up 10% this year, including the day's move</p><p> (Reporting by John Biju in Bengaluru)</p><p> ((John.Biju@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Australia's Prescient Therapeutics soars on EU orphan drug tag for cancer therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Australia's Prescient Therapeutics soars on EU orphan drug tag for cancer therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-19 08:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Australia's <a href=\"https://laohu8.com/S/PTX.AU\">Prescient Therapeutics</a> soars on EU orphan drug tag for cancer therapy </title></head><body><p>** Shares of Prescient <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>PTX.AX</span> rise as much as 29.2% to A$0.062, their highest level since December 23, 2024</p><p>** Clinical-stage oncology company heading for best day since December 2024, if gains hold</p><p>** Co says European Medicines Agency <span>grants</span> orphan drug designation to PTX-100 for treating cutaneous T-cell lymphoma</p><p>** About 4.4 million shares change hand, 3.9x 30-day average</p><p>** Stock up 10% this year, including the day's move</p><p> (Reporting by John Biju in Bengaluru)</p><p> ((John.Biju@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PTX.AU","symbol_name":"PRESCIENT THERAPEUTICS LTD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nL6N3WV00V:1","article_id":"2584960552","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584960552","pubTimestamp":1763512912,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Australia's Prescient Therapeutics soars on EU orphan drug tag for cancer therapy** Shares of Prescient Therapeutics PTX.AX rise as much as 29.2% to A$0.062, their highest level since December 23, 2024** Clinical-stage oncology company heading for best day since December 2024, if gains hold** Co says European Medicines Agency grants orphan drug designation to PTX-100 for treating cutaneous T-cell lymphoma** About 4.4 million shares change hand, 3.9x 30-day average** Stock up 10% this year, including the day's move  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PTX.AU":"PRESCIENT THERAPEUTICS LTD","BK7067":"生物科技","BK7508":"医药生物股"},"translate_title":"BUZZ-澳大利亚的Prescient Therapeutics在欧盟癌症治疗孤儿药标签上飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PTX.AU":0.9},"content_text":"BUZZ-Australia's Prescient Therapeutics soars on EU orphan drug tag for cancer therapy ** Shares of Prescient Therapeutics PTX.AX rise as much as 29.2% to A$0.062, their highest level since December 23, 2024** Clinical-stage oncology company heading for best day since December 2024, if gains hold** Co says European Medicines Agency grants orphan drug designation to PTX-100 for treating cutaneous T-cell lymphoma** About 4.4 million shares change hand, 3.9x 30-day average** Stock up 10% this year, including the day's move (Reporting by John Biju in Bengaluru) ((John.Biju@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}